Madiha Derouazi
Hoofd Techniek/Wetenschap/O&O bij AC IMMUNE SA
Vermogen: 7 271 $ op 30-04-2024
Profiel
Madiha Derouazi is the founder and current Chief Executive Officer & Director of Amal Therapeutics SA, which is founded in 2012.
She is also currently the Chief Scientific Officer at AC Immune SA, where she started in 2024.
Dr. Derouazi has a graduate degree from the Technical University of Berlin and a doctorate degree from the Swiss Federal Institute of Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
AC IMMUNE SA
0.00% | 01-03-2024 | 3 175 ( 0.00% ) | 7 271 $ | 30-04-2024 |
Actieve functies van Madiha Derouazi
| Bedrijven | Functie | Begin |
|---|---|---|
| AC IMMUNE SA | Hoofd Techniek/Wetenschap/O&O | 01-01-2024 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Oprichter | 03-09-2012 |
Eerdere bekende functies van Madiha Derouazi
| Bedrijven | Functie | Einde |
|---|
Opleiding van Madiha Derouazi
| Technical University of Berlin | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
